For the treatment of non-small cell lung cancer (NSCLC), molecularly targeted agents are already an integral part of therapeutic algorithms, including the inhibitors of the epidermal growth factor receptor (EGFR), including erlotinib, gefitinib, and osimertinib [8,9,10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.